KINGSEY
FALLS, QC, Nov. 6, 2024 /PRNewswire/ - Cascades Inc.
(TSX: CAS) reports its unaudited financial results for the
three-month period ended September 30,
2024.
Q3 2024 Highlights
- Sales of $1,201 million (compared
with $1,180 million in Q2 2024 and
$1,198 million in Q3 2023);
- Operating income of $36 million
(compared with $34 million in Q2 2024
and $80 million in Q3 2023);
- Net earnings per common share of $0.01 (compared with $0.01 in Q2 2024 and $0.34 in Q3 2023);
- Adjusted earnings before interest, taxes, depreciation and
amortization (EBITDA (A)1) of $140 million (compared with $112 million in Q2 2024 and $161 million in Q3 2023);
- Adjusted net earnings per common share1 of
$0.27 (compared with $0.08 in Q2 2024 and $0.44 in Q3 2023);
- Net debt1 of $2,039
million as of September 30,
2024 (compared with $2,093
million as of June 30, 2024).
Net debt to EBITDA (A) ratio1 of 4.3x, versus from 4.2x
as of June 30, 2024;
- Total capital expenditures, net of disposals, totaled
$34 million in Q3 2024, compared to
$23 million in Q2 2024 and
$56 million in Q3 2023. The
Corporation's 2024 capital expenditures will be approximately
$160 million.
Hugues Simon, President and CEO,
commented: "We are pleased with our third quarter 2024 performance.
Sequentially stronger results were driven by our Containerboard
business, where higher average selling prices and lower production
expenses offset the impact of higher raw material costs. Specialty
Products results were stable, with stronger selling prices fully
mitigating raw material cost and sales mix headwinds. As
forecasted, third quarter Tissue Papers results were lower than the
previous quarter due to higher average raw material costs and lower
pricing related to the expected changes in the mix of products
sold."
Discussing near-term outlook, Mr. Simon commented, "We expect
fourth quarter results in each of our packaging business segments
to be stable sequentially, as benefits from lower raw material
costs and previously announced selling price increases will be
offset by lower seasonal volumes. In Tissue Papers, slightly
stronger sequential results are expected to benefit from lower
average raw material costs, slightly stronger volumes, and selling
price increase tailwinds offset by the impact from seasonal changes
in sales mix.
As we look toward the medium and longer-term, we are focused on
growing sustainable value for shareholders. Central to this is
driving and capturing efficiency across our operational platforms,
most notably by the ongoing scale-up of production at our
Bear Island facility and ramp-up
of our recently installed tissue converting lines. Prioritizing
these areas, in conjunction with leveraging additional production
capacity in all of our facilities through numerous efficiency
optimization initiatives, will drive cash flow generation and debt
reduction, both of which are key action areas across the Company.
We will be all the more better positioned to deliver on both fronts
as we implement the changes announced on October 30, and look forward to sharing details
of our areas of strategic focus for the next 18 to 24 months in
early 2025."
1
|
Some information
represents non-IFRS Accounting Standards Financial measures, other
financial measures or non-IFRS Accounting Standards ratios which
are not standardized under IFRS Accounting Standards and therefore
might not be comparable to similar financial measures disclosed by
other corporations. Please refer to the "Supplemental Information
on Non-IFRS Accounting Standards Measures and Other Financial
Measures" section for a
complete reconciliation.
|
Financial Summary
Selected consolidated information
(in millions of
Canadian dollars, except amounts per common share)
(unaudited)
|
Q3
2024
|
Q2 2024
|
Q3 2023
|
|
|
|
|
Sales
|
1,201
|
1,180
|
1,198
|
As
Reported
|
|
|
|
Operating
income
|
36
|
34
|
80
|
Net
earnings
|
1
|
1
|
34
|
per common share
(basic)
|
$0.01
|
$0.01
|
$0.34
|
Adjusted1
|
|
|
|
Earnings before
interest, taxes, depreciation and amortization (EBITDA
(A))
|
140
|
112
|
161
|
Net
earnings
|
27
|
8
|
45
|
per common share
(basic)
|
$0.27
|
$0.08
|
$0.44
|
Margin (EBITDA (A) /
Sales)
|
11.7 %
|
9.5 %
|
13.4 %
|
Segmented sales
(in millions of
Canadian dollars) (unaudited)
|
Q3
2024
|
Q2 2024
|
Q3 2023
|
|
|
|
|
Packaging
Products
|
|
|
|
Containerboard
|
610
|
585
|
593
|
Specialty
Products
|
169
|
167
|
157
|
Inter-segment
sales
|
(6)
|
(7)
|
(7)
|
|
773
|
745
|
743
|
Tissue
Papers
|
390
|
397
|
422
|
Inter-segment sales,
Corporate, Recovery and Recycling activities
|
38
|
38
|
33
|
Sales
|
1,201
|
1,180
|
1,198
|
Segmented operating income (loss)
(in millions of
Canadian dollars) (unaudited)
|
Q3
2024
|
Q2 2024
|
Q3 2023
|
|
|
|
|
Packaging
Products
|
|
|
|
Containerboard
|
24
|
15
|
61
|
Specialty
Products
|
17
|
19
|
13
|
|
|
|
|
Tissue
Papers
|
24
|
38
|
38
|
|
|
|
|
Corporate, Recovery and
Recycling activities
|
(29)
|
(38)
|
(32)
|
Operating
income
|
36
|
34
|
80
|
Segmented EBITDA (A)1
(in millions of
Canadian dollars) (unaudited)
|
Q3
2024
|
Q2 2024
|
Q3 2023
|
|
|
|
|
Packaging
Products
|
|
|
|
Containerboard
|
90
|
60
|
101
|
Specialty
Products
|
27
|
26
|
21
|
|
|
|
|
Tissue
Papers
|
43
|
54
|
61
|
|
|
|
|
Corporate, Recovery and
Recycling activities
|
(20)
|
(28)
|
(22)
|
EBITDA
(A)1
|
140
|
112
|
161
|
1 Please refer to
the "Supplemental Information on Non-IFRS Accounting Standards
Measures and Other Financial Measures" section for a complete
reconciliation.
|
Analysis of results for the three-month period ended
September 30, 2024 (compared to the same period last
year)
The Corporation's third quarter sales of $1,201 million increased by $3 million compared with the same period last
year. This was driven by $24 million of sales mix benefits in
Tissue Papers and Containerboard, and $12 million related to
more a favourable foreign exchange. Results also reflected a
consolidated $7 million net benefit from higher selling
prices. These were offset by a net negative impact of
$40 million related to lower volumes in Containerboard and
Tissue Papers, with the majority of this impact attributable to the
changes made within the Tissue Papers operational platform in the
past year to improve profitability.
The third quarter EBITDA (A)1 totaled $140 million, a decrease of $21 million, or
13%, from the $161 million generated
in the same period last year. This reflects consolidated net
impacts of $35 million from higher raw material costs and
$5 million related to volume and sales mix changes. These were
partly offset by net benefits from higher selling prices and lower
operating costs, and lower corporate costs, as expected.
The main specific items, before income taxes, that impacted our
third quarter 2024 operating income and/or net earnings were:
- $7 million of impairment charge
on assets related to a decision to discontinue product lines in
Canada and in the United States (operating income and net
earnings);
- $29 million of restructuring and
other costs related to plant closures in Canada (operating income and net
earnings);
- $2 million unrealized gain on
financial instruments (operating income and net earnings);
- $2 million unrealized loss on
interest rate hedge instruments (net earnings);
- $1 million foreign exchange gain
on long-term debt and financial instruments net earnings.
For the three-month period ended September 30, 2024,
the Corporation posted net earnings of $1
million, or $0.01 per common
share, compared to net earnings of $34
million, or $0.34 per common
share, in the same period of 2023. On an adjusted
basis1, the Corporation posted net earnings of
$27 million in the third quarter of 2024, or $0.27 per common share, compared to net earnings
of $45 million, or $0.44 per
common share, in the same period of 2023.
1 Please refer to
the "Supplemental Information on Non-IFRS Accounting Standards
Measures and Other Financial Measures" section for a complete
reconciliation.
|
Dividend on common shares and normal course issuer
bid
The Board of Directors of Cascades declared a quarterly dividend
of $0.12 per common share to be paid
on December 5, 2024 to shareholders
of record at the close of business on November 21, 2024. This dividend is an "eligible
dividend" as per the Income Tax Act (R.C.S. (1985), Canada). During the third quarter of 2024,
Cascades purchased no common shares for cancellation.
2024 Third Quarter Results Conference Call
Details
Management will discuss the 2024 third quarter financial results
during a conference call today at 9:00 a.m.
ET. The call can be accessed by dialing 1-800-990-4777
(international 1-289-819-1299). The conference call, including the
investor presentation, will be broadcast live on the Cascades
website (www.cascades.com) under the "Investors" section. A replay
of the call will be available on the Cascades website and may also
be accessed by phone until December 7,
2024 by dialing 1-888-660-6345 (international
1-289-819-1450), access code 18522 #.
Founded in 1964, Cascades offers sustainable, innovative and
value-added packaging, hygiene and recovery solutions. The company
employs approximately 9,700 women and men across a network of
close to 70 facilities in North
America. Driven by its participative management, half a
century of experience in recycling, and continuous research and
development efforts, Cascades continues to provide innovative
products that customers have come to rely on, while contributing to
the well-being of people, communities and the entire planet.
Cascades' shares trade on the Toronto Stock Exchange under the
ticker symbol CAS. Certain statements in this release, including
statements regarding future results and performance, are
forward-looking statements based on current expectations. The
accuracy of such statements is subject to a number of risks,
uncertainties and assumptions that may cause actual results to
differ materially from those projected, including, but not limited
to, the effect of general economic conditions, decreases in demand
for the Corporation's products, increases in raw material costs,
fluctuations in selling prices and adverse changes in general
market and industry conditions and other factors.
CONSOLIDATED BALANCE SHEETS
(in millions of
Canadian dollars) (unaudited)
|
September
30,
2024
|
December 31,
2023
|
Assets
|
|
|
Current
assets
|
|
|
Cash and cash
equivalents
|
34
|
54
|
Accounts
receivable
|
495
|
453
|
Current income tax
assets
|
8
|
12
|
Inventories
|
643
|
568
|
Current portion of
financial assets
|
2
|
1
|
|
1,182
|
1,088
|
Long-term
assets
|
|
|
Investments in
associates and joint ventures
|
99
|
94
|
Property, plant and
equipment
|
2,753
|
2,808
|
Intangible assets with
finite useful life
|
44
|
55
|
Other assets
|
106
|
78
|
Deferred income tax
assets
|
192
|
167
|
Goodwill and other
intangible assets with indefinite useful life
|
488
|
482
|
|
4,864
|
4,772
|
Liabilities and
Equity
|
|
|
Current
liabilities
|
|
|
Bank loans and
advances
|
7
|
—
|
Trade and other
payables
|
678
|
703
|
Current income tax
liabilities
|
4
|
6
|
Current portion of
Unsecured senior notes of $175 million to be refinanced
|
175
|
—
|
Current portion of
long-term debt
|
63
|
67
|
Current portion of
provisions for contingencies and charges
|
16
|
14
|
Current portion of
financial liabilities and other liabilities
|
28
|
29
|
|
971
|
819
|
Long-term
liabilities
|
|
|
Long-term
debt
|
1,828
|
1,869
|
Provisions for
contingencies and charges
|
89
|
61
|
Financial
liabilities
|
3
|
5
|
Other
liabilities
|
94
|
94
|
Deferred income tax
liabilities
|
129
|
143
|
|
3,114
|
2,991
|
Equity
|
|
|
Capital
stock
|
616
|
613
|
Contributed
surplus
|
16
|
15
|
Retained
earnings
|
1,045
|
1,096
|
Accumulated other
comprehensive income
|
31
|
15
|
Equity attributable
to Shareholders
|
1,708
|
1,739
|
Non-controlling
interests
|
42
|
42
|
Total
equity
|
1,750
|
1,781
|
|
4,864
|
4,772
|
CONSOLIDATED STATEMENTS OF EARNINGS (LOSS)
|
For the 3-month
periods ended September 30,
|
For the 9-month
periods ended September 30,
|
(in millions of
Canadian dollars, except per common share amounts and number of
common shares) (unaudited)
|
2024
|
2023
|
2024
|
2023
|
Sales
|
1,201
|
1,198
|
3,490
|
3,500
|
|
|
|
|
|
Supply chain and
logistic
|
736
|
711
|
2,126
|
2,064
|
Wages and employee
benefits expenses
|
267
|
266
|
809
|
809
|
Depreciation and
amortization
|
70
|
69
|
206
|
199
|
Maintenance and
repair
|
58
|
60
|
180
|
178
|
Other operational
costs
|
—
|
—
|
20
|
13
|
Impairment
charges
|
7
|
7
|
9
|
161
|
Other loss
(gain)
|
24
|
1
|
27
|
(1)
|
Restructuring
costs
|
5
|
4
|
38
|
11
|
Unrealized loss (gain)
on derivative financial instruments
|
(2)
|
—
|
(4)
|
2
|
Operating
income
|
36
|
80
|
79
|
64
|
Financing
expense
|
36
|
38
|
108
|
92
|
Share of results of
associates and joint ventures
|
(5)
|
(4)
|
(14)
|
(19)
|
Earnings (loss)
before income taxes
|
5
|
46
|
(15)
|
(9)
|
Provision for
(recovery of) income taxes
|
(1)
|
6
|
(8)
|
(9)
|
Net earnings (loss)
including non-controlling interests for the period
|
6
|
40
|
(7)
|
—
|
Net earnings
attributable to non-controlling interests
|
5
|
6
|
11
|
19
|
Net earnings (loss)
attributable to Shareholders for the period
|
1
|
34
|
(18)
|
(19)
|
Net earnings (loss)
per common share
|
|
|
|
|
Basic
|
$0.01
|
$0.34
|
($0.18)
|
($0.19)
|
Diluted
|
$0.01
|
$0.34
|
($0.18)
|
($0.19)
|
Weighted average
basic number of common shares outstanding
|
100,988,040
|
100,669,311
|
100,824,800
|
100,493,892
|
Weighted average
number of diluted common shares
|
101,042,159
|
101,163,731
|
101,042,799
|
100,910,246
|
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(LOSS)
|
For the 3-month
periods ended September 30,
|
For the 9-month
periods ended September 30,
|
(in millions of
Canadian dollars) (unaudited)
|
2024
|
2023
|
2024
|
2023
|
Net earnings (loss)
including non-controlling interests for the period
|
6
|
40
|
(7)
|
—
|
Other comprehensive
income (loss)
|
|
|
|
|
Items that may be
reclassified subsequently to earnings
|
|
|
|
|
Translation
adjustments
|
|
|
|
|
Change in foreign
currency translation of foreign subsidiaries
|
(14)
|
24
|
24
|
—
|
Change in foreign
currency translation related to net investment hedging
activities
|
6
|
(10)
|
(9)
|
(1)
|
Cash flow
hedges
|
|
|
|
|
Change in fair value
of commodity derivative financial instruments
|
1
|
1
|
1
|
(4)
|
Recovery of
(provision for) income taxes
|
(1)
|
1
|
1
|
1
|
|
(8)
|
16
|
17
|
(4)
|
Items that are not
released to earnings
|
|
|
|
|
Actuarial gain (loss)
on employee future benefits
|
(4)
|
2
|
7
|
5
|
Recovery of (provision
for) income taxes
|
1
|
—
|
(2)
|
(1)
|
|
(3)
|
2
|
5
|
4
|
Other comprehensive
income (loss)
|
(11)
|
18
|
22
|
—
|
Comprehensive income
(loss) including non-controlling interests for the
period
|
(5)
|
58
|
15
|
—
|
Comprehensive income
attributable to non-controlling interests for
the period
|
5
|
6
|
12
|
19
|
Comprehensive income
(loss) attributable to Shareholders for
the period
|
(10)
|
52
|
3
|
(19)
|
CONSOLIDATED STATEMENTS OF EQUITY
|
For the 9-month
period ended September 30, 2024
|
(in millions of
Canadian dollars) (unaudited)
|
CAPITAL
STOCK
|
CONTRIBUTED
SURPLUS
|
RETAINED
EARNINGS
|
ACCUMULATED OTHER
COMPREHENSIVE INCOME
|
TOTAL EQUITY
ATTRIBUTABLE TO SHAREHOLDERS
|
NON-CONTROLLING
INTERESTS
|
TOTAL EQUITY
|
Balance - Beginning
of period
|
613
|
15
|
1,096
|
15
|
1,739
|
42
|
1,781
|
Comprehensive income
(loss)
|
|
|
|
|
|
|
|
Net earnings
(loss)
|
—
|
—
|
(18)
|
—
|
(18)
|
11
|
(7)
|
Other comprehensive
income
|
—
|
—
|
5
|
16
|
21
|
1
|
22
|
|
—
|
—
|
(13)
|
16
|
3
|
12
|
15
|
Dividends
|
—
|
—
|
(36)
|
—
|
(36)
|
(12)
|
(48)
|
Stock options
expense
|
—
|
2
|
—
|
—
|
2
|
—
|
2
|
Issuance of common
shares upon exercise of stock options
|
3
|
(1)
|
—
|
—
|
2
|
—
|
2
|
Acquisition of
non-controlling interests
|
—
|
—
|
(2)
|
—
|
(2)
|
—
|
(2)
|
Balance - End of
period
|
616
|
16
|
1,045
|
31
|
1,708
|
42
|
1,750
|
|
|
|
|
|
|
|
|
|
For the 9-month period
ended September 30, 2023
|
(in millions of
Canadian dollars) (unaudited)
|
CAPITAL
STOCK
|
CONTRIBUTED
SURPLUS
|
RETAINED
EARNINGS
|
ACCUMULATED OTHER
COMPREHENSIVE INCOME
|
TOTAL EQUITY
ATTRIBUTABLE TO SHAREHOLDERS
|
NON-CONTROLLING
INTERESTS
|
TOTAL EQUITY
|
Balance - Beginning
of period
|
611
|
14
|
1,212
|
34
|
1,871
|
57
|
1,928
|
Comprehensive
income
|
|
|
|
|
|
|
|
Net earnings
(loss)
|
—
|
—
|
(19)
|
—
|
(19)
|
19
|
—
|
Other comprehensive
income (loss)
|
—
|
—
|
4
|
(4)
|
—
|
—
|
—
|
|
—
|
—
|
(15)
|
(4)
|
(19)
|
19
|
—
|
Dividends
|
—
|
—
|
(36)
|
—
|
(36)
|
(33)
|
(69)
|
Stock options
expense
|
—
|
1
|
—
|
—
|
1
|
—
|
1
|
Issuance of common
shares upon exercise of stock options
|
2
|
—
|
—
|
—
|
2
|
—
|
2
|
Acquisition of
non-controlling interests
|
—
|
—
|
1
|
—
|
1
|
(1)
|
—
|
Balance - End of
period
|
613
|
15
|
1,162
|
30
|
1,820
|
42
|
1,862
|
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
For the 3-month
periods ended September 30,
|
For the 9-month
periods ended September 30,
|
(in millions of
Canadian dollars) (unaudited)
|
2024
|
2023
|
2024
|
2023
|
Operating
activities
|
|
|
|
|
Net earnings (loss)
attributable to Shareholders for the period
|
1
|
34
|
(18)
|
(19)
|
Adjustments
for:
|
|
|
|
|
Financing
expense
|
36
|
38
|
108
|
92
|
Depreciation and
amortization
|
70
|
69
|
206
|
199
|
Impairment
charges
|
7
|
7
|
9
|
161
|
Other loss
(gain)
|
24
|
1
|
27
|
(1)
|
Restructuring
costs
|
5
|
4
|
38
|
11
|
Unrealized loss (gain)
on derivative financial instruments
|
(2)
|
—
|
(4)
|
2
|
Provision for (recovery
of) income taxes
|
(1)
|
6
|
(8)
|
(9)
|
Share of results of
associates and joint ventures
|
(5)
|
(4)
|
(14)
|
(19)
|
Net earnings
attributable to non-controlling interests
|
5
|
6
|
11
|
19
|
Net financing expense
paid
|
(48)
|
(47)
|
(113)
|
(109)
|
Net income taxes
paid
|
(1)
|
(2)
|
(4)
|
(9)
|
Dividends
received
|
—
|
—
|
9
|
7
|
Provisions for
contingencies and charges and other liabilities
|
(15)
|
(12)
|
(61)
|
(19)
|
|
76
|
100
|
186
|
306
|
Changes in non-cash
working capital components
|
26
|
40
|
(68)
|
(36)
|
|
102
|
140
|
118
|
270
|
Investing
activities
|
|
|
|
|
Disposals in associates
and joint ventures
|
—
|
—
|
—
|
10
|
Payments for property,
plant and equipment
|
(35)
|
(59)
|
(116)
|
(303)
|
Proceeds from disposals
of property, plant and equipment
|
1
|
3
|
18
|
6
|
Change in intangible
and other assets
|
—
|
—
|
(20)
|
(1)
|
|
(34)
|
(56)
|
(118)
|
(288)
|
Financing
activities
|
|
|
|
|
Bank loans and
advances
|
4
|
(5)
|
7
|
(3)
|
Change in credit
facilities
|
(22)
|
(132)
|
63
|
34
|
Change in credit
facilities without recourse to the Corporation
|
(6)
|
99
|
12
|
99
|
Payments of other
long-term debt, including lease obligations (2024 -
$50 million for the 9-month period ($15 million for the
3-month period); 2023 - $44 million for the 9-month period
($15 million for the 3-month period))
|
(17)
|
(26)
|
(54)
|
(117)
|
Issuance of common
shares upon exercise of stock options
|
—
|
—
|
2
|
2
|
Dividends paid to
non-controlling interests
|
(4)
|
(24)
|
(12)
|
(33)
|
Acquisition of
non-controlling interests
|
—
|
—
|
(3)
|
(3)
|
Dividends paid to the
Corporation's Shareholders
|
(12)
|
(12)
|
(36)
|
(36)
|
|
(57)
|
(100)
|
(21)
|
(57)
|
Net change in cash
and cash equivalents during the period
|
11
|
(16)
|
(21)
|
(75)
|
Currency translation
on cash and cash equivalents
|
—
|
1
|
1
|
(1)
|
Cash and cash
equivalents - Beginning of the period
|
23
|
41
|
54
|
102
|
Cash and cash
equivalents - End of the period
|
34
|
26
|
34
|
26
|
SEGMENTED INFORMATION
The Corporation's operations are managed in three segments:
Containerboard and Specialty Products (these two segments
constitute the Corporation's Packaging Products) and Tissue Papers.
The accounting policies of the reportable segments are the same as
the Corporation's accounting policies described in Note 2.
The Corporation's operating segments are reported in a manner
consistent with the internal reporting provided to the chief
operating decision-maker (CODM). The Chief Executive Officer has
authority for resource allocation and management of the
Corporation's performance and is therefore the CODM. The CODM
assesses the performance of each reportable segment based on sales
and earnings before interest, taxes, depreciation and amortization,
adjusted to exclude specific items (EBITDA (A)). The CODM
considers EBITDA (A) to be the best performance measure of the
Corporation's activities.
Sales for each segment are prepared on the same basis as those
of the Corporation. Inter-segment operations are recorded on the
same basis as sales to third parties, which are at fair market
value.
EBITDA (A) does not have a standardized meaning under IFRS
Accounting Standards; accordingly, it may not be comparable to
similarly named measures used by other companies. Investors should
not view EBITDA (A) as an alternative measure to, for example, net
earnings, or as a measure of operating results, which are IFRS
Accounting Standards measures.
Sales by country by business segment are shown in the
following table:
|
|
|
|
|
|
|
SALES TO
|
|
|
|
For the 3-month
periods ended September 30,
|
|
Canada
|
United
States
|
Other
countries
|
Total
|
(in millions of
Canadian dollars) (unaudited)
|
2024
|
2023
|
2024
|
2023
|
2024
|
2023
|
2024
|
2023
|
Packaging
Products
|
|
|
|
|
|
|
|
|
Containerboard
|
360
|
339
|
250
|
254
|
—
|
—
|
610
|
593
|
Specialty
Products
|
66
|
60
|
102
|
95
|
1
|
2
|
169
|
157
|
Inter-segment
sales
|
(4)
|
(4)
|
(2)
|
(3)
|
—
|
—
|
(6)
|
(7)
|
|
422
|
395
|
350
|
346
|
1
|
2
|
773
|
743
|
Tissue
Papers
|
144
|
148
|
246
|
274
|
—
|
—
|
390
|
422
|
Inter-segment sales,
Corporate, Recovery and Recycling activities
|
28
|
24
|
9
|
7
|
1
|
2
|
38
|
33
|
|
594
|
567
|
605
|
627
|
2
|
4
|
1,201
|
1,198
|
|
|
|
|
|
|
|
SALES TO
|
|
|
|
For the 9-month
periods ended September 30,
|
|
Canada
|
United
States
|
Other
countries
|
Total
|
(in millions of
Canadian dollars) (unaudited)
|
2024
|
2023
|
2024
|
2023
|
2024
|
2023
|
2024
|
2023
|
Packaging
Products
|
|
|
|
|
|
|
|
|
Containerboard
|
1,028
|
997
|
720
|
718
|
3
|
1
|
1,751
|
1,716
|
Specialty
Products
|
192
|
174
|
301
|
304
|
3
|
4
|
496
|
482
|
Inter-segment
sales
|
(12)
|
(12)
|
(8)
|
(11)
|
—
|
—
|
(20)
|
(23)
|
|
1,208
|
1,159
|
1,013
|
1,011
|
6
|
5
|
2,227
|
2,175
|
Tissue
Papers
|
412
|
410
|
742
|
815
|
—
|
—
|
1,154
|
1,225
|
Inter-segment sales,
Corporate, Recovery and Recycling activities
|
84
|
72
|
24
|
20
|
1
|
8
|
109
|
100
|
|
1,704
|
1,641
|
1,779
|
1,846
|
7
|
13
|
3,490
|
3,500
|
EBITDA (A) by business segment is reconciled to IFRS
Accounting Standards measure, namely operating income (loss), and
is shown in the following table:
|
For the 3-month
period ended September 30, 2024
|
(in millions of
Canadian dollars) (unaudited)
|
Containerboard
|
Specialty
Products
|
Tissue
Papers
|
Corporate,
Recovery
and Recycling activities
|
Consolidated
|
Operating income
(loss)
|
24
|
17
|
24
|
(29)
|
36
|
Depreciation and
amortization
|
38
|
6
|
16
|
10
|
70
|
Impairment
charges
|
—
|
4
|
3
|
—
|
7
|
Other loss
|
24
|
—
|
—
|
—
|
24
|
Restructuring
costs
|
5
|
—
|
—
|
—
|
5
|
Unrealized gain on
derivative financial instruments
|
(1)
|
—
|
—
|
(1)
|
(2)
|
EBITDA
(A)
|
90
|
27
|
43
|
(20)
|
140
|
|
For the 3-month period
ended September 30, 2023
|
(in millions of
Canadian dollars) (unaudited)
|
Containerboard
|
Specialty
Products
|
Tissue
Papers
|
Corporate, Recovery
and
Recycling activities
|
Consolidated
|
Operating income
(loss)
|
61
|
13
|
38
|
(32)
|
80
|
Depreciation and
amortization
|
38
|
6
|
15
|
10
|
69
|
Impairment
charges
|
2
|
—
|
5
|
—
|
7
|
Other loss
|
—
|
1
|
—
|
—
|
1
|
Restructuring
costs
|
—
|
1
|
3
|
—
|
4
|
EBITDA
(A)
|
101
|
21
|
61
|
(22)
|
161
|
|
For the 9-month
period ended September 30, 2024
|
(in millions of
Canadian dollars) (unaudited)
|
Containerboard
|
Specialty
Products
|
Tissue
Papers
|
Corporate, Recovery
and Recycling activities
|
Consolidated
|
Operating income
(loss)
|
32
|
55
|
93
|
(101)
|
79
|
Depreciation and
amortization
|
113
|
18
|
42
|
33
|
206
|
Impairment
charges
|
2
|
4
|
3
|
—
|
9
|
Other loss
|
27
|
—
|
—
|
—
|
27
|
Restructuring
costs
|
27
|
1
|
9
|
1
|
38
|
Unrealized gain on
derivative financial instruments
|
(1)
|
—
|
—
|
(3)
|
(4)
|
EBITDA
(A)
|
200
|
78
|
147
|
(70)
|
355
|
|
For the 9-month period
ended September 30, 2023
|
(in millions of
Canadian dollars) (unaudited)
|
Containerboard
|
Specialty
Products
|
Tissue
Papers
|
Corporate, Recovery and
Recycling activities
|
Consolidated
|
Operating income
(loss)
|
161
|
53
|
(36)
|
(114)
|
64
|
Depreciation and
amortization
|
102
|
16
|
50
|
31
|
199
|
Impairment
charges
|
61
|
1
|
99
|
—
|
161
|
Other loss
(gain)
|
—
|
1
|
(2)
|
—
|
(1)
|
Restructuring
costs
|
—
|
1
|
10
|
—
|
11
|
Unrealized loss (gain)
on derivative financial instruments
|
(1)
|
—
|
—
|
3
|
2
|
EBITDA
(A)
|
323
|
72
|
121
|
(80)
|
436
|
Payments for property, plant and equipment by business
segment are shown in the following table:
|
PAYMENTS FOR PROPERTY,
PLANT AND EQUIPMENT
|
|
For the 3-month
periods ended September 30,
|
For the 9-month
periods ended September 30,
|
(in millions of
Canadian dollars) (unaudited)
|
2024
|
2023
|
2024
|
2023
|
Packaging
Products
|
|
|
|
|
Containerboard
|
23
|
29
|
92
|
184
|
Specialty
Products
|
8
|
8
|
16
|
19
|
|
31
|
37
|
108
|
203
|
Tissue
Papers
|
12
|
6
|
32
|
23
|
Corporate, Recovery
and Recycling activities
|
10
|
16
|
29
|
29
|
Total
acquisitions
|
53
|
59
|
169
|
255
|
Right-of-use assets
acquisitions (non-cash)
|
(19)
|
(11)
|
(73)
|
(26)
|
|
34
|
48
|
96
|
229
|
Acquisitions for
property, plant and equipment included in "Trade and other
payables"
|
|
|
|
|
Beginning of the
period
|
26
|
43
|
45
|
106
|
End of the
period
|
(25)
|
(32)
|
(25)
|
(32)
|
Payments for
property, plant and equipment
|
35
|
59
|
116
|
303
|
Proceeds from
disposals of property, plant and equipment
|
(1)
|
(3)
|
(18)
|
(6)
|
Payments for
property, plant and equipment net of proceeds from
disposals
|
34
|
56
|
98
|
297
|
SUPPLEMENTAL INFORMATION ON NON-IFRS ACCOUNTING STANDARDS
MEASURES AND OTHER FINANCIAL MEASURES
SPECIFIC ITEMS
The Corporation incurs some specific items that adversely or
positively affect its operating results. We believe it is useful
for readers to be aware of these items as they provide additional
information to measure performance, compare the Corporation's
results between periods, and assess operating results and
liquidity, notwithstanding these specific items. Management
believes these specific items are not necessarily reflective of the
Corporation's underlying business operations in measuring and
comparing its performance and analyzing future trends. Our
definition of specific items may differ from that of other
corporations and some of these items may arise in the future and
may reduce the Corporation's available cash.
They include, but are not limited to, charges for (reversals of)
impairment of assets, restructuring gains or costs, loss on
refinancing and repurchase of long-term debt, some deferred tax
asset provisions or reversals, premiums paid on repurchase of
long-term debt, gains or losses on the acquisition or sale of a
business unit, gains or losses on the share of results of
associates and joint ventures, unrealized gains or losses on
derivative financial instruments that do not qualify for hedge
accounting, unrealized gains or losses on interest rate hedge
instruments and option fair value revaluation, foreign exchange
gains or losses on long-term debt and financial instruments, fair
value revaluation gains or losses on investments, specific items of
discontinued operations and other significant items of an unusual,
non-cash or non-recurring nature.
RECONCILIATION AND USES OF NON-IFRS ACCOUNTING STANDARDS
MEASURES AND OTHER FINANCIAL MEASURES
To provide more information for evaluating the Corporation's
performance, the financial information included in this analysis
contains certain data that are not performance measures under IFRS
Accounting Standards ("non-IFRS Accounting Standards measures"),
which are also calculated on an adjusted basis to exclude specific
items. We believe that providing certain key performance and
capital measures, as well as non-IFRS Accounting Standards
measures, is useful to both Management and investors, as they
provide additional information to measure the performance and
financial position of the Corporation. This also increases the
transparency and clarity of the financial information. The
following non-IFRS Accounting Standards measures and other
financial measures are used in our financial disclosures:
Non-IFRS Accounting Standards measures
- Adjusted earnings before interest, taxes, depreciation and
amortization or EBITDA (A): represents the operating income (as
published in the Consolidated Statement of Earnings (Loss) of the
Consolidated Financial Statements) before depreciation and
amortization excluding specific items. Measure used to assess
recurring operating performance and the contribution of each
segment on a comparable basis.
- Adjusted net earnings: Measure used to assess the Corporation's
consolidated financial performance on a comparable basis.
- Adjusted cash flow: Measure used to assess the Corporation's
capacity to generate cash flows to meet financial obligations
and/or discretionary items such as share repurchases, dividend
increases and strategic investments.
- Free cash flow: Measure used to calculate the excess cash the
Corporation generates by subtracting capital expenditures
(excluding strategic projects) from the EBITDA (A).
- Working capital: Measure used to assess the short-term
liquidity of the Corporation.
Other financial measures
- Total debt: Measure used to calculate all the Corporation's
debt, including long-term debt and bank loans. Often put in
relation to equity to calculate the debt-to-equity ratio.
- Net debt: Measure used to calculate the Corporation's total
debt less cash and cash equivalents. Often put in relation to
EBITDA (A) to calculate net debt to EBITDA (A) ratio.
Non-IFRS Accounting Standards ratios
- Net debt to EBITDA (A) ratio: Ratio used to assess the
Corporation's ability to pay its debt and evaluate financial
leverage.
- EBITDA (A) margin: Ratio used to assess operating performance
and the contribution of each segment on a comparable basis
calculated as a percentage of sales.
- Adjusted net earnings per common share: Ratio used to assess
the Corporation's consolidated financial performance on a
comparable basis.
- Ratio of net debt / (total equity and net debt): Ratio used to
evaluate the Corporation's financial leverage and the risk to
Shareholders.
- Working capital as a percentage of sales: Ratio used to assess
the Corporation's operating liquidity performance.
- Adjusted cash flow per common share: Ratio used to assess the
Corporation's financial flexibility.
- Free cash flow ratio: Ratio used to measure the liquidity and
efficiency of how much more cash the Corporation generates than it
uses to run the business by subtracting capital expenditures
(excluding strategic projects) from the EBITDA (A) calculated as a
percentage of sales.
Non-IFRS Accounting Standards measures and other financial
measures are mainly derived from the consolidated financial
statements, but do not have meanings prescribed by IFRS Accounting
Standards. These measures have limitations as an analytical tool
and should not be considered on their own or as a substitute for an
analysis of our results as reported under IFRS Accounting
Standards. In addition, our definitions of non-IFRS Accounting
Standards measures and other financial measures may differ from
those of other corporations. Any such modification or reformulation
may be significant.
The CODM assesses the performance of each reportable segment
based on sales and earnings before interest, taxes, depreciation
and amortization, adjusted to exclude specific items
(EBITDA (A)1). The CODM considers EBITDA
(A)1 to be the best performance measure of the
Corporation's activities.
EBITDA (A)1 by business segment is reconciled to IFRS
Accounting Standards measure, namely operating income (loss), and
is shown in the following table:
|
Q3
2024
|
(in millions of
Canadian dollars) (unaudited)
|
Containerboard
|
Specialty
Products
|
Tissue
Papers
|
Corporate, Recovery
and Recycling activities
|
Consolidated
|
Operating income
(loss)
|
24
|
17
|
24
|
(29)
|
36
|
Depreciation and
amortization
|
38
|
6
|
16
|
10
|
70
|
Impairment
charges
|
—
|
4
|
3
|
—
|
7
|
Other loss
|
24
|
—
|
—
|
—
|
24
|
Restructuring
costs
|
5
|
—
|
—
|
—
|
5
|
Unrealized gain on
derivative financial instruments
|
(1)
|
—
|
—
|
(1)
|
(2)
|
EBITDA
(A)1
|
90
|
27
|
43
|
(20)
|
140
|
|
Q2 2024
|
(in millions of
Canadian dollars) (unaudited)
|
Containerboard
|
Specialty
Products
|
Tissue
Papers
|
Corporate, Recovery and
Recycling activities
|
Consolidated
|
Operating income
(loss)
|
15
|
19
|
38
|
(38)
|
34
|
Depreciation and
amortization
|
38
|
6
|
13
|
12
|
69
|
Restructuring
costs
|
6
|
1
|
3
|
—
|
10
|
Unrealized loss (gain)
on derivative financial instruments
|
1
|
—
|
—
|
(2)
|
(1)
|
EBITDA
(A)1
|
60
|
26
|
54
|
(28)
|
112
|
|
Q3 2023
|
(in millions of
Canadian dollars) (unaudited)
|
Containerboard
|
Specialty
Products
|
Tissue
Papers
|
Corporate, Recovery and
Recycling activities
|
Consolidated
|
Operating income
(loss)
|
61
|
13
|
38
|
(32)
|
80
|
Depreciation and
amortization
|
38
|
6
|
15
|
10
|
69
|
Impairment
charges
|
2
|
—
|
5
|
—
|
7
|
Other loss
|
—
|
1
|
—
|
—
|
1
|
Restructuring
costs
|
—
|
1
|
3
|
—
|
4
|
EBITDA
(A)1
|
101
|
21
|
61
|
(22)
|
161
|
1 Please refer to
the "Supplemental Information on Non-IFRS Accounting Standards
Measures and Other Financial Measures" section for a complete
reconciliation.
|
The following table reconciles net earnings and net earnings per
common share, as reported, with adjusted net earnings1
and adjusted net earnings per common share1:
(in millions of
Canadian dollars, except per common share amounts and number of
common shares) (unaudited)
|
NET
EARNINGS
|
|
NET
EARNINGS
PER COMMON
SHARE2
|
|
Q3
2024
|
Q2 2024
|
Q3 2023
|
|
Q3
2024
|
Q2 2024
|
Q3 2023
|
As
reported
|
1
|
1
|
34
|
|
$0.01
|
$0.01
|
$0.34
|
Specific
items:
|
|
|
|
|
|
|
|
Impairment
charges
|
7
|
—
|
7
|
|
$0.06
|
—
|
$0.05
|
Other loss
|
24
|
—
|
1
|
|
$0.18
|
—
|
—
|
Restructuring
costs
|
5
|
10
|
4
|
|
$0.03
|
$0.07
|
$0.03
|
Unrealized gain on
derivative financial instruments
|
(2)
|
(1)
|
—
|
|
($0.01)
|
($0.01)
|
—
|
Unrealized loss on
interest rate hedge instrument
|
2
|
1
|
—
|
|
$0.01
|
$0.01
|
—
|
Foreign exchange loss
(gain) on long-term debt and financial instruments
|
(1)
|
—
|
2
|
|
($0.01)
|
—
|
$0.02
|
Tax effect on specific
items, other tax adjustments and attributable to non-controlling
interest2
|
(9)
|
(3)
|
(3)
|
|
—
|
—
|
—
|
|
26
|
7
|
11
|
|
$0.26
|
$0.07
|
$0.10
|
Adjusted1
|
27
|
8
|
45
|
|
$0.27
|
$0.08
|
$0.44
|
Weighted average
basic number of common shares outstanding
|
|
|
|
|
100,988,040
|
100,781,388
|
100,669,311
|
The following table reconciles cash flow from operating
activities with EBITDA (A)1:
(in millions of
Canadian dollars) (unaudited)
|
Q3
2024
|
Q2 2024
|
Q3 2023
|
Cash flow from
operating activities
|
102
|
54
|
140
|
Changes in non-cash
working capital components
|
(26)
|
24
|
(40)
|
Net income taxes paid
(received)
|
1
|
(2)
|
2
|
Net financing expense
paid
|
48
|
18
|
47
|
Provisions for
contingencies and charges and other liabilities, net of dividends
received
|
15
|
18
|
12
|
EBITDA
(A)1
|
140
|
112
|
161
|
The following table reconciles cash flow from operating
activities with cash flow from operating activities (excluding
changes in non-cash working capital components) and adjusted cash
flow from operating activities1. It also reconciles
adjusted cash flow from operating activities1 to
adjusted cash flow generated (used)1, which is also
calculated on a per common share basis:
(in millions of
Canadian dollars, except per common share amounts or otherwise
noted) (unaudited)
|
Q3
2024
|
Q2 2024
|
Q3 2023
|
Cash flow from
operating activities
|
102
|
54
|
140
|
Changes in non-cash
working capital components
|
(26)
|
24
|
(40)
|
Cash flow from
operating activities (excluding changes in non-cash working capital
components)
|
76
|
78
|
100
|
Restructuring costs
paid
|
10
|
17
|
6
|
Adjusted cash flow
from operating activities1
|
86
|
95
|
106
|
Payments for property,
plant and equipment
|
(35)
|
(40)
|
(59)
|
Change in intangible
and other assets
|
—
|
(20)
|
—
|
Lease obligation
payments
|
(15)
|
(15)
|
(15)
|
Proceeds from
disposals of property, plant and equipment
|
1
|
17
|
3
|
|
37
|
37
|
35
|
Dividends paid to
non-controlling interests
|
(4)
|
(5)
|
(24)
|
Dividends paid to the
Corporation's Shareholders and to non-controlling
interests
|
(12)
|
(12)
|
(12)
|
Adjusted cash flow
generated (used)1
|
21
|
20
|
(1)
|
Adjusted cash flow
generated (used) per common share1
(in Canadian
dollars)
|
$0.21
|
$0.20
|
($0.01)
|
Weighted average
basic number of common shares outstanding
|
100,988,040
|
100,781,388
|
100,669,311
|
1 Please refer to
the "Supplemental Information on Non-IFRS Accounting Standards
Measures and Other Financial Measures" section for a complete
reconciliation.
|
2 Specific amounts
per common share are calculated on an after-tax basis and are net
of the portion attributable to non-controlling interests. Per share
amounts in line item ''Tax effect on specific items, other tax
adjustments and attributable to non-controlling interests'' only
include the effect of tax adjustments.
|
The following table reconciles total debt1 and net
debt1 with the ratio of net debt to adjusted earnings
before interest, taxes, depreciation and amortization (EBITDA
(A))1:
(in millions of
Canadian dollars) (unaudited)
|
September
30,
2024
|
June 30,
2024
|
September
30,
2023
|
Long-term
debt
|
1,828
|
1,878
|
2,048
|
Current portion of
Unsecured senior notes of $175 million to be refinanced
|
175
|
175
|
—
|
Current portion of
long-term debt
|
63
|
60
|
66
|
Bank loans and
advances
|
7
|
3
|
—
|
Total
debt1
|
2,073
|
2,116
|
2,114
|
Less: Cash and cash
equivalents
|
(34)
|
(23)
|
(26)
|
Net debt1 as reported
|
2,039
|
2,093
|
2,088
|
Last twelve months
EBITDA (A)1
|
477
|
498
|
552
|
Net debt / EBITDA
(A) ratio1
|
4.3x
|
4.2x
|
3.8x
|
1 Please refer to
the "Supplemental Information on Non-IFRS Accounting Standards
Measures and Other Financial Measures" section for a complete
reconciliation.
|
View original
content:https://www.prnewswire.com/news-releases/cascades-reports-results-for-the-third-quarter-of-2024-302297908.html
SOURCE Cascades Inc.